Abstract
A phase II trial of R-MACLO-IVAM followed by thalidomide maintenance for mantle cell lymphoma (MCL) demonstrated promising progression-free survival (PFS) and overall survival (OS) rates. Thalidomide maintenance was associated with significant toxicity and was subsequently modified to rituximab maintenance. Herein, we present updated results and follow-up. Two sequential phase II trials included chemotherapy-naïve patients with MCL up to 75 years old. Four cycles of R-MACLO-IVAM chemotherapy were delivered as previously described. Patients who achieved complete responses (CR) were eligible for thalidomide or rituximab maintenance therapy. Among 36 patients enrolled, the MCL International Prognostic Index (MIPI) was low in 53%, intermediate in 36% and high in 11%. Thirty-five patients completed at least 2 cycles of chemotherapy; 34 (94%) achieved a CR. After a median follow-up of 74.4 months, the 5-year PFS was 51% (95% CI 33-68%) and the 5-year OS was 85% (95% CI 73-97%). Two deaths occurred during the chemotherapy phase due to disease progression and neutropenic sepsis, respectively. One patient developed secondary acute myeloid leukemia after 7 years. R-MACLO-IVAM chemotherapy is effective for patients with newly diagnosed MCL.
References
Mar 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E ZuccaF Cavalli
Jan 31, 1998·British Journal of Haematology·E VandenbergheD C Linch
Dec 16, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I F KhouriR Champlin
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
May 29, 2004·Blood·Hannes KaufmannJohannes Drach
Jan 26, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Georg LenzWolfgang Hiddemann
Sep 8, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E RomagueraFernando F Cabanillas
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Veronica FernàndezAndreas Rosenwald
Oct 27, 2007·Blood·Eva HosterUNKNOWN European Mantle Cell Lymphoma Network
Jul 16, 2008·Blood·Christian H GeislerUNKNOWN Nordic Lymphoma Group
Feb 28, 2009·British Journal of Haematology·Thomas M HabermannJoseph M Tuscano
Dec 30, 2009·Leukemia & Lymphoma·Izidore S LossosGail R Walker
Jun 22, 2012·Blood·Richard DelarueUNKNOWN Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Aug 10, 2012·The New England Journal of Medicine·H C Kluin-NelemansM H Dreyling
Oct 2, 2012·Leukemia & Lymphoma·Martin DreylingUNKNOWN European MCL Network
Oct 18, 2012·Blood·Erinn SouciePatrice Dubreuil
Mar 19, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S H BernsteinR I Fisher
Citations
Apr 14, 2017·Hematology/oncology and Stem Cell Therapy·Jose D Sandoval-SusBijal D Shah
Jun 25, 2019·Current Opinion in Oncology·Igor Aurer
Mar 30, 2017·PloS One·Xuan ZhouJuan Li
Mar 19, 2021·American Journal of Hematology·Juan P AlderuccioIzidore S Lossos
Apr 10, 2021·Archives of Pathology & Laboratory Medicine·Jessica Alvarez-LesmesJulio Poveda